GPER/GPR30 Knockout Mice: Effects of GPER on Metabolism

Part of the Methods in Molecular Biology book series (MIMB, volume 1366)

Abstract

Endogenous estrogens, predominantly 17β-estradiol (E2), mediate various diverse effects throughout the body in both normal physiology and disease. Actions include development (including puberty) and reproduction as well as additional effects throughout life in the metabolic, endocrine, musculoskeletal, nervous, cardiovascular, and immune systems. The actions of E2 have traditionally been attributed to the classical nuclear estrogen receptors (ERα and ERβ) that largely mediate transcriptional/genomic activities. However, more recently the G protein-coupled estrogen receptor GPER/GPR30 has become recognized as an essential mediator of certain, and particularly rapid, signaling events in response to E2. Murine genetic knockout (KO) models represent an important approach to understand the mechanisms of E2 action in physiology and disease. Studies of GPER KO mice over the last years have revealed functions for GPER in the regulation of obesity, insulin resistance and glucose intolerance, among other areas of (patho)physiology. This chapter focuses on methods for the evaluation of metabolic parameters in vivo and ex vivo with an emphasis on glucose homeostasis and metabolism through the use of glucose and insulin tolerance tests, pancreatic islet and adipocyte isolation and characterization.

Key words

Estrogen GPER GPR30 Metabolism Obesity Adipose Adipocyte Insulin resistance Insulin sensitivity Glucose tolerance Type 2 diabetes 

Notes

Acknowledgments

The authors have been supported by NIH grants CA116662, CA127731, and CA163890 (ERP) and the UNM Cancer Center (CA118100).

Disclosures: E.R.P. is an inventor on US patents assigned to the University of New Mexico for GPER-selective ligands and imaging agents.

References

  1. 1.
    Ogden CL, Yanovski SZ, Carroll MD, Flegal KM (2007) The epidemiology of obesity. Gastroenterology 132:2087–2102CrossRefGoogle Scholar
  2. 2.
    Sherwin R, Jastreboff AM (2012) Year in diabetes 2012: the diabetes tsunami. J Clin Endocrinol Metab 97:4293–4301CrossRefGoogle Scholar
  3. 3.
    Chen L, Magliano DJ, Zimmet PZ (2012) The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nat Rev Endocrinol 8:228–236CrossRefGoogle Scholar
  4. 4.
    Faulds MH, Zhao C, Dahlman-Wright K, Gustafsson JA (2012) The diversity of sex steroid action: regulation of metabolism by estrogen signaling. J Endocrinol 212:3–12CrossRefGoogle Scholar
  5. 5.
    Barton M (2013) Cholesterol and atherosclerosis: modulation by oestrogen. Curr Opin Lipidol 24:214–220CrossRefGoogle Scholar
  6. 6.
    Meyer MR, Clegg DJ, Prossnitz ER, Barton M (2011) Obesity, insulin resistance and diabetes: sex differences and role of oestrogen receptors. Acta Physiol (Oxf) 203:259–269CrossRefGoogle Scholar
  7. 7.
    Nedungadi TP, Clegg DJ (2009) Sexual dimorphism in body fat distribution and risk for cardiovascular diseases. J Cardiovasc Transl Res 2:321–327CrossRefGoogle Scholar
  8. 8.
    Clegg DJ (2012) Minireview: the year in review of estrogen regulation of metabolism. Mol Endocrinol 26:1957–1960CrossRefGoogle Scholar
  9. 9.
    Mauvais-Jarvis F, Clegg DJ, Hevener AL (2013) The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev 34:309–338CrossRefGoogle Scholar
  10. 10.
    Tiano JP, Mauvais-Jarvis F (2012) Importance of oestrogen receptors to preserve functional beta-cell mass in diabetes. Nat Rev Endocrinol 8:342–351CrossRefGoogle Scholar
  11. 11.
    Barros RP, Gustafsson JA (2011) Estrogen receptors and the metabolic network. Cell Metab 14:289–299CrossRefGoogle Scholar
  12. 12.
    Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr (2000) Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB- EGF. Mol Endocrinol 14:1649–1660CrossRefGoogle Scholar
  13. 13.
    Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER (2005) A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307:1625–1630CrossRefGoogle Scholar
  14. 14.
    Thomas P, Pang Y, Filardo EJ, Dong J (2005) Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146:624–632CrossRefGoogle Scholar
  15. 15.
    Prossnitz ER, Arterburn JB (2015) International Union of Basic and Clinical Pharmacology: G protein-coupled estrogen receptor (GPER) and its pharmacologic modulators. Pharmacol Rev 67(3):505–540CrossRefGoogle Scholar
  16. 16.
    Barton M, Prossnitz ER (2015) Emerging roles of GPER in diabetes and atherosclerosis. Trends Endocrinol Metab 26(4):185–192CrossRefGoogle Scholar
  17. 17.
    Prossnitz ER, Barton M (2014) Estrogen biology: new insights into GPER function and clinical opportunities. Mol Cell Endocrinol 389:71–83CrossRefGoogle Scholar
  18. 18.
    Prossnitz ER, Barton M (2011) The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol 7:715–726CrossRefGoogle Scholar
  19. 19.
    Dennis MK, Field AS, Burai R et al (2011) Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J Steroid Biochem Mol Biol 127:358–366CrossRefGoogle Scholar
  20. 20.
    Dennis MK, Burai R, Ramesh C et al (2009) In vivo effects of a GPR30 antagonist. Nat Chem Biol 5:421–427CrossRefGoogle Scholar
  21. 21.
    Bologa CG, Revankar CM, Young SM et al (2006) Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2:207–212CrossRefGoogle Scholar
  22. 22.
    Prossnitz ER, Hathaway HJ (2015) What have we learned about GPER function in physiology and disease from knockout mice? J Steroid Biochem Mol Biol (in press).Google Scholar
  23. 23.
    Sharma G, Hu C, Brigman JL, Zhu G, Hathawa HJ, Prossnitz ER (2013) GPER deficiency in male mice results in insulin resistance, dyslipidemia, and a proinflammatory state. Endocrinology 154:4136–4145CrossRefGoogle Scholar
  24. 24.
    Sharma G, Prossnitz ER (2011) Mechanisms of estradiol-induced insulin secretion by the G protein-coupled estrogen receptor GPR30/GPER in pancreatic beta-cells. Endocrinology 152:3030–3039CrossRefGoogle Scholar
  25. 25.
    Martensson UE, Salehi SA, Windahl S et al (2009) Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology 150:687–698CrossRefGoogle Scholar
  26. 26.
    Romacho T, Elsen M, Rohrborn D, Eckel J (2014) Adipose tissue and its role in organ crosstalk. Acta Physiol (Oxf) 210:733–753CrossRefGoogle Scholar
  27. 27.
    McGown C, Birerdinc A, Younossi ZM (2014) Adipose tissue as an endocrine organ. Clin Liver Dis 18:41–58CrossRefGoogle Scholar
  28. 28.
    Exley MA, Hand L, O’Shea D, Lynch L (2014) Interplay between the immune system and adipose tissue in obesity. J Endocrinol 223:R41–R48CrossRefGoogle Scholar
  29. 29.
    Tchernof A, Despres JP (2013) Pathophysiology of human visceral obesity: an update. Physiol Rev 93:359–404CrossRefGoogle Scholar
  30. 30.
    Poitout V, Robertson RP (2008) Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 29:351–36630.Google Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Internal Medicine and UNM Comprehensive Cancer CenterUniversity of New Mexico Health Sciences CenterAlbuquerqueUSA

Personalised recommendations